Bile acid sequestrants, fibrates, nicotinic acid, and omega 3 fatty acids by all Sub-ICB Locations

Why it matters: NICE guideline NG238 (cardiovascular disease: risk assessment and reduction, including lipid modification) recommends that fibrates, nicotinic acid, bile acid sequestrants, and omega-3 fatty acid compounds (excluding icosapent ethyl) should not be routinely offered to patients for the primary or secondary prevention of cardiovascular disease (CVD). In particular, NICE state that there is no evidence that omega 3 fatty acid compounds help to prevent CVD (with the exception of icosapent ethyl). This guidance does not apply to people with familial hypercholesterolaemia, which is covered by separate NICE guidance.

Description: Total cost of prescriptions for bile acid sequestrants, fibrates, nicotinic acid, and omega 3 fatty acid compounds per 1000 registered patients

Performance: Loading...


Tagged as: Cardiovascular system, Standard, Efficacy, NICE (or browse all measures)

Sub-ICB Locations are ordered by mean percentile over the past six months. Each chart shows the results for the individual Sub-ICB Location, plus deciles across all Sub-ICB Locations in the NHS in England.

View measure for NHS England combined →

Fetching data...

Do you need help with your analysis? Don't forget to check the FAQ page, and get in touch if you have questions.